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Background: Although agonistic autoantibodies against type-1 angiotensin-II receptor (AT1-AA) are frequently
detected in women with preeclampsia, the clinical significance of AT1-AA in association with epithelial ovarian
cancer (EOC) has not been identified.
Methods: In an attempt to clarify this issue, we measured serum AT1-AA titer from EOC patients (n = 89) and
healthy normal subjects (n = 55), correlated AT1-AA titer with EOC stage and grade, and demonstrated the effects of
purified AT1-AA on migration of ovarian cancer cells and angiogenesis of chick embryo chorioallantoic membrane.
Results: We found that the AT1-AA titer was significantly higher in EOC patients compared with healthy control
subjects (1.77 ± 0.28 vs. 0.35 ± 0.05, P < 0.01). The positive rate was averaged by 72.1±2.5% in EOC patients and
15.5 ±1.5% in control (P < 0.01). Increased AT1-AA titer in EOC patients was associated with advanced stages and
grades of EOC, and positively correlated with level of vascular endothelial growth factor (r = 0.855, P < 0.01).
Furthermore, AT1-AA directly stimulated migration of ovarian cancer cells and enhanced microvascular density of
chick embryo chorioallantoic membrane. These AT1-AA-mediated effects were significantly blocked either by an
autoantibody-neutralizing peptide or an angiotensin II type I receptor antagonist, losartan.
Conclusion: Taken together, we found that a higher serum AT1-AA titer may be associated with advanced
progression of EOC in patients and play an important role in development of EOC by promoting cancer cell
migration and angiogenesis. These findings implicate that AT1-AA might be selected as a detectable biomarker and
potential therapeutic target in diagnosis and treatment of EOC patients.
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Epithelial ovarian cancerBackground
Epithelial ovarian cancer (EOC) is the sixth most com-
mon cancer and the seventh cause of death worldwide
among women who develop gynecological cancer [1],
with the estimated 22,280 new cases and 15,500 deaths
in the United States in 2012. The vast majority of EOC
patients are usually diagnosed with advanced stages due
to the lack of adequate early screening tests and early
specific symptoms during development of EOC [2]. The* Correspondence: liuhr2000@126.com
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reproduction in any medium, provided the orstandard treatment for advanced EOC patients includes
debulking surgery followed by platinum–taxane based
chemotherapy. These patients, however, are also at great
risk of recurrence and emerging drug resistance with a
more than 70% of relapse rate and a mean 18 months of
progression-free survival period [2,3]. Therefore, under-
standing the pathogenesis of EOC and identifying early
detectable biomarkers are essential to improve overall
survival rate in advanced EOC patient.
It has well been defined that angiotensin II (Ang II)
derived from the activated renin-angiotensin system
plays a key role in the regulation of cardiovasculartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(AT1) and type 2 (AT2) receptors, which maintain arter-
ial blood pressure, fluid and electrolyte homeostasis.
Through the AT2 receptor, Ang II evokes vasodilatation,
sodium excretion and blood pressure reduction, and
thereby counteracts the effects of AT1 receptor [4].
However, increasing evidence suggests that Ang II is also
involved in tumor cell migration/invasion, angiogenesis
and metastasis through AT1 receptor during the tumor
development [5-7]. In patient with EOC, it has previ-
ously been reported that Ang II enhances vascular endo-
thelial growth factor (VEGF) secretion, angiogenesis and
tumor cell invasion via up-regulating G-protein-coupled
AT1 receptor; importantly, angiogenesis and peritoneal
dissemination of the EOC can selectively be blocked
using AT1 receptor antagonist [6,8]. Therefore, consider-
able effort has been placed on the development of Ang II
blockade therapy as a new strategy for EOC treatment.
Recent studies have demonstrated that agonistic auto-
antibodies against type-1 angiotensin II receptor (AT1-
AA) detected in preeclampsia induces significant placental
trophoblast invasion [9], suggesting that AT1-AA is one of
the potential causative factors in development of pre-
eclampsia. We have previously reported that AT1-AA con-
stricts human fetoplacental blood vessels and restricts
fetal perfusion through activating Ang II AT1 receptor
[10]. Although animals studies have shown that activation
of AT1-AA is associated with elevation of intracellular Ca
2+
in vascular smooth muscle cells [11], stimulation of pla-
cental and vascular NADPH oxidase [12] and activation of
NF-κB [13], all of which may cause inflammation and con-
tribute to pathogenesis of preeclampsia via AT1-AA, there
is less specific data to show whether AT1-AA is elevated
in patient with EOC and correlated with the advanced
progression of EOC. Therefore, in the current study, we
examined the serum AT1-AA titer in EOC patients and
determined whether change in AT1-AA level is associated
with malignant grades and angiogenic factor, VEGF. Using
AT1-AA purified from EOC patients, we demonstrated
the effects of AT1-AA on migration of ovarian cancer cells
and microvascular density of chick embryo chorioallantoic
membrane. Furthermore, we investigated whether the
AT1-AA-elicited biological effects could be suppressed by
autoantibody-neutralizing AT1-AA peptide, and whether
cell migration and angiogenesis stimulated by AT1-AA
could be blocked by Ang II AT1 receptor antagonist.
Methods
Patients
The study included 89 malignant EOC patients who
were diagnosed and operated in the third hospital of
Capital Medical University during the period of 05/2010
to 04/2012. Cases were chosen based on the histological
grades and clinical stages of EOC patients according tothe International Federation of Gynecology and Obstetrics
(FIGO) criteria. The healthy control subjects (n = 55) were
enrolled from laparoscopy-negative cases on the clinical
assessment at the same hospital. No significant difference
in age was found between these two groups. The consent
form was signed by all patients and the research protocol
was approved by the Institutional Committee for the Pro-
tection of Human Subjects of Capital Medical University.
Cases were excluded if patients were associated with
1) autoimmune diseases and endocrinal diseases; 2) com-
plications derived from other different organ systems;
3) immune deficiencies diseases; 4) significant gastrointes-
tinal diseases. All clinical and laboratory data were
recorded. Serum samples were collected from the patients
in both groups and stored at −80°C until use.
Measurement of AT1-AA titer and VEGF by enzyme-linked
immunosorbent assay (ELISA)
The serum AT1-AA level in patients was detected by
ELISA as we reported previously [10]. Briefly, 96-well mi-
crotiter plates were coated with 1 μg/ml AT1R-ECII pep-
tide synthesized from patients (GL Biochem Ltd,
Shanghai, China) and incubated overnight at 4°C. After
washing the plates with PBS three times, 50 μl serum sam-
ples were added to the plates and incubated at 37°C for
1 h. The biotinylated goat anti-human IgG antibody
(1:3,000, Zhongshan Inc., Beijing, China) or streptavidin-
peroxidase conjugate (1:2,000 Vector, CA, USA) was then
incubated separately at 37°C for 1 h during washings. Fi-
nally, 2, 2-azino-di (3-ethylbenzothiazoline) sulphonic acid
(ABTS)-H2O2 (Roche, Basel, Switzerland) substrate buffer
was applied for a half hour before reading. The optical
densities (OD) from these plates were measured at 405 nm
in a plate reader (Molecular Devices Corp, CA, USA). The
AT1-AA titer was expressed as the ratio of positive/nega-
tive (P/N), i.e., (the OD of specimen - the OD of blank
control) / (the OD of negative control - the OD of blank
control). The positivity of the serum sample to AT1-AA
was defined as P/N ≥ 2.1, while the negativity was defined
as P/N ≤ 1.5. All assays were performed in duplicate. Com-
mercially accessible ELISA kit (DaKeWe Biotechnological
Corp, Shengzheng, China) were used to determine the pa-
tients’ serum VEGF level according to the manufacturer’s
instructions. VEGF concentration was expressed as ng/L
and the assays were performed in duplicate.
AT1-AA peptide synthesis
AT1-AA peptide fragments equivalent to the sequence
of human anti-AT1 receptor antibody (AT1R-ECII, 165–
191, I-H-R-N-V-F-F-I-I-N-T-N-I-T-V-C-A-F-H-Y-E-S-Q-
N-S-T-L) was synthesized by solid-phase peptide synthesis
method (GL Biochem Ltd, Shanghai, China). The purity of
synthetic peptide was confirmed with a high pressure li-
quid chromatography as we reported previously [10].
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The total immunoglobulin G was isolated from serum
samples with AT1-AA positive EOC patients or AT1-AA
negative healthy normal subjects by Mab Trap Kit
(Amersham, NJ, USA). The purities of extractions were
assessed by sodium dodecylsulfonate–polyacrylate gel elec-
trophoresis (SDS–PAGE) as we reported previously [10].Table 1 Patient characteristics
Characteristic Number
Age at diagnosis 51 + 8.2
Weight (kg) 62 + 8.9
BMI (kg/m2) 25 + 4.1
Age at menarche 15 + 2.0
Age at menopause 47 + 4.2
Stage
I 6 (6.7%)Cell lines and cell migration assay
Human ovarian cancer cells (OVCAR3) were purchased
from the Cancer Hospital of Chinese Academy of Med-
ical Sciences, Beijing, China and maintained in DMEM
supplemented with 10% FBS, 2 mM l-glutamine, 100
units/ml penicillin and 100 μg/ml streptomycin. For all
experiments, cells were detached with 0.25% trypsin and
0.02% EDTA and washed once in complete medium be-
fore use. Migration assay was conducted according to
the manufacture’s recommended protocol (BD Biosci-
ences, New Jersey, USA). Briefly, OVCAR3 at 5 × 104
concentration were suspended in 300 μl of serum free
media in the upper chamber with pre-coated filters
(6.5 mm in diameter and 8 μm pore-size) with or with-
out AT1-AA, Ang II, AT1R-ECII or Ang II AT1 receptor
antagonist, losartan. Bottom chambers were filled with
medium containing 10% FBS as a chemoattractant. After
cells were allowed to seed on the chambers for 24 h at
37°C, cells on the upper chamber and migrated cells at
the bottom chamber were wiped with a cotton swab and
then mixed with staining solution containing 0.125%
coomassie blue in a mixture of methanol, acetic acid and
water in a ratio of 45:10:45. The results were visualized
under an inverted microscope from 5 randomized high
power fields (x400). Results were calculated from the
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Values are mean ± SE; others represent the percentage of total patients.Visualization of microvascular density in chick embryo
chorioallantoic membrane (CAM)
Fertilized white leghorn chicken eggs were received at
day 0 and incubated for 3 days at 37°C with constant hu-
midity. On day 3, eggs were rinsed with 70% ethanol and
a square window (0.5 cm2) was made with a pair of ster-
ile scissor and cut away a circle of shell, thus exposing
the underlying membrane (the chorioallantois). After the
eggs (n = 8/each group) were treated with saline, AT1-
AA, Ang II, AT1R-ECII or losartan, respectively for
30 min, the window was sealed with transparent tape
and the eggs returned to the incubator at 90% relative
humidity without turning. After 72 h of incubation, the
CAM was fixed using 3.7% formaldehyde for 15 min, cut
3 cm2 from the center and mounted on the slides for ob-
servation. The angiogenic results were visualized on an
inverted microscope from 5 randomized fields. For each
experiment, the staggered images were digitized andresults were calculated as a mean of microvascular dens-
ity per high power field (x 400).
Statistical analysis
All data were calculated as mean ± SE. Statistical analysis
was performed with SPSS 15.0 software. The positive
rates in the two groups were compared with chi-square
test. The t-test was applied for comparing two independ-
ent sample means, and the one-way ANOVA was used
for comparing means of more than two samples.
P < 0.05 was considered to be statistically significant.
Results
Clinical characteristics presented in EOC patients
Patient characteristics, stage and grade are shown in
Table 1. The mean age of the EOC at primary diagnosis
was 50.4±11 years and the mean history of the EOC was
7.4 ± 6 years. The mean age of the EOC at menarche was
15±2, and at menopause was 47±4. The FIGO stage of
EOC patients was classified as follows: I: 6%; II: 56%; III:
23%; IV: 4%. Most EOC patients were at the grade III
(61%). Fifty-four patients (28%) had ascites whereas 31%
patients had no such complication.
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The serum AT1-AA titer in EOC patients and healthy
control subjects was measured by ELISA. As shown in
Figure 1A, the serum AT1-AA titer was significantly in-
creased from 0.35 ± 0.05 in healthy normal subjects to
1.77 ± 0.28 in EOC patients (P < 0.01). The average posi-
tive rate of AT1-AA in EOC patients was significantly
higher than that in healthy normal subjects (72.1%±2.5%
vs. 15.5%±1.9%, P < 0.01). The correlation of serum AT1-
AA with clinicopathological outcomes was analyzed in
EOC patients. As shown in Figure 1B, the number of
AT1-AA positive patients was increased with clinical
FIGO stage: 45% in stage 1, 61.5% in stage II and 72.8% in
advanced stage III. Moreover, the AT1-AA titer was also
significantly higher in patients with an advanced grade
(Figure 1C): 61.7% in grade 1, 72.7% in grade II and 80.1%
in grade 3. These results indicated that AT1-AA level in-
creases with progression of EOC stage and grade.
Correlation between serum AT1-AA titer and VEGF
To determine whether serum AT1-AA titer is associated
with angiogenesis of the tumor, we examined the serum
level of VEGF by ELISA in the same series of EOC pa-
tients. As shown in Figure 2A and 2B, VEGF level was
significantly increased in patients with advanced FIGO
stage and grade (i.e., at level III) compared with those in
an early FIGO stage and grade (i.e., at level I). Positive lin-
ear correlation among the serum AT1-AA level and VEGF
was detected, (Figure 2C, r2 = 0.855, p < 0.01), suggesting
that AT1-AA may play a role in angiogenesis during devel-
opment of EOC through enhancing VEGF expression.
Effect of AT1-AA on migration of ovarian cancer cells
OVCAR3 cells derived from the progressive adenocar-
cinoma of the ovary were used in this study. Migration
of OVCAR3 cells stimulated by adding AT1-AA was en-
hanced in a dose-dependent manner. As shown in the
top panel of Figure 3, cell migration rates were conse-
quently increased relative to the control when cells were
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Figure 1 Level of AT1-AA in EOC patients. Relative to the healthy norma
The number of AT1-AA positive patients was associated with clinical FIGO s
subjects (Nor); † P < 0.05 vs. the stage I and grade I, respectively.for 24 h. To demonstrate the potency of AT1-AA in
stimulation of cell migration by activating angiotensin
AT1 receptor, OVCAR3 cells were treated either with ex-
ogenous AT1-AA (100 nM) or Ang II (100 nM), respect-
ively before subjecting to cell migration. As shown at the
bottom panel of Figure 3, both AT1-AA and Ang II pro-
duced a comparable level in cell migration. Stimulation by
AT1-AA (100 nM) on cell migration was completely
blocked either by the AT1R-ECII (100 nM) or by the se-
lective Ang II AT1 receptor antagonist, losartan (300 nM),
suggesting that AT1-AA has direct stimulating effect on
tumor cell migration and enhancement of OVCAR3 cell
migration by AT1-AA is mediated by Ang II AT1 receptor.
Addition of losartan or AT1R-EC II alone had no effect on
migration of OVCAR3 cells.
Effect of AT1-AA on angiogenesis of the CAM
AT1-AA administration caused a significant increase in
microvascular density in the CAM. Figure 4 shows the
representative photographs of AT1-AA-treated and sa-
line control CAM. Quantitatively, in each of the six ex-
periments, the microvascular density of the CAM treated
with AT1-AA (100 nM) was increased by 60-70% com-
pared with saline control. Addition of Ang II (100 nM)
also increased the microvascular density of the CAM to a
comparable level as that found in the AT1-AA treated
CAM. Enhancement in the microvascular density by AT1-
AA was significantly blocked either by AT1R-ECII (100
nM) or losartan (300 nM), suggesting a role of AT1-AA in
angiogenesis through stimulating Ang II AT1 receptor.
Simultaneous addition of only the AT1R-ECII (100 nM) or
the losartan (300 nM), without AT1-AA or Ang II, did not
affect the microvascular density when compared with sa-
line control (Figure 4).
Discussion
These results are the first to demonstrate that AT1-AA
level is significantly elevated in EOC patients. Enhanced
AT1-AA titer was associated with advanced stage and
grade of the EOC and positively correlated with VEGF stage
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l subjects, AT1-AA titer was significantly increased in EOC patients (A).
tage (B) and grade (C). Values are mean ± SE. *p < 0.05 vs. the normal



























































Figure 2 VEGF level in EOC patients and healthy normal subjects. Increased level of VEGF was detected in advanced stage (A) and grade
(B). Scatter plots showed a positive linear correlation between VEGF level and AT1-AA titer in EOC patients (C). Values are mean ± SE. *p < 0.05 vs.
the normal subjects (Nor); † P < 0.05 vs. the stage I and grade I, respectively.
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CAM of chick embryo, we found that AT1-AA has direct
effect on cell migration and angiogenesis through acti-
vating Ang II AT1 receptor.
AT1-AA, an autoantibody against angiotensin II type 1
receptor, which is characterized to activate the receptor
via specifically interacting with the second extracellular
loop of the Ang II AT1 receptor, has been documented to
play a role in the pathogenesis of preeclampsia and hyper-
tension [10,11,13-15]. However, AT1-AA level and func-
tion has not been examined or identified in the ovarian
cancer. In the current study, we found that serum titer























































Figure 3 Effect of AT1-AA on migration of OVCAR3 cells. AT1-AA increa
the control (A), cell migration by AT1-AA was significantly enhanced (B), wh
migration by AT1-AA was blocked either by AT1-AA-ECII (D) or losartan (E).
(Nor); †P < 0.05 vs. AT1-AA and Ang II. HPF = high power field (x 400).in EOC patients. More importantly, this study revealed
that the level of AT1-AA is significantly elevated with an
advanced FGIO stage and grade in EOC patients,
supporting the concept that AT1-AA may participate in
ovarian cancer development and progression. As it has
well been demonstrated, the FIGO stage and grade are
poor prognostic factors for overall survival in EOC pa-
tients [3]. Therefore, monitoring serum AT1-AA level
might be of great value as a single marker in detecting all
stages of EOC patients for clinical screening test, diagnosis
and prognosis after therapeutic intervention.
VEGF is a main angiogenic factor in development of
ovarian cancer through promoting angiogenesis andA
B C
D E
sed migration in a dose-dependent manner (top panel). Relative to
ich is comparable to the level found in Ang II (C). Enhancement of



























Figure 4 Effect of AT1-AA on angiogenesis of the CAM. Relative to the saline control (A), AT1-AA significantly increased microvascular density
of the CAM (B) to a comparable level as did by Ang II (C). Enhancement of microvascular density by AT1-AA was blocked either by AT1-AA-ECII
(D) or Ang II AT1 receptor antagonist, losartan (E). Values are mean ± SE. n = 6 for each group. *p < 0.05 vs. saline control (Nor); †P < 0.05 vs.
AT1-AA and Ang II. HPF = high power field (x400).
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prognosis [16-18]. Recent studies have shown that
targeting inhibition of tumor angiogenesis through
VEGF and its various signaling pathways is an effective
therapy to suppress tumor growth and progression
[8,17]. Our results showed that higher AT1-AA titer is
positively correlated with VEGF level in advanced stages
of EOC patients, consistent with previous findings show-
ing a role of Ang II in cancer development through
VEGF gene expression and secretion [8,17].
Stimulation of AT1 receptor by Ang II has been
reported to be involved in tumor progression in a num-
ber of cancers including EOC [12,13]. The postulated
role of AT1-AA in cell migration and tumor spread led
us to test if AT1-AA has direct stimulating effect on
ovarian cell migration. We selected either autoantibody-
neutralizing AT1-AA peptide, AT1R-ECII as an inhibitor
or selective AT1 receptor antagonist, losartan to test the
direct effect of AT1-AA on cell migration and illustrate
if this process is mediated by AT1 receptor [11]. We
found that the migratory number of OVCAR3 cells was
significantly increased in AT1-AA treated group, which
was blocked either by AT1R-ECII or losartan. These data
suggested that AT1-AA has direct effect on migration of
ovarian cancer cells through activating AT1 receptor,
consistent with a previous report showing that Ang II-
induced tumor cell invasion, angiogenesis and peritoneal
dissemination are blocked by Ang II AT1-receptor antag-
onist [19]. However, mechanistic studies are needed to
further elucidate how AT1-AA activates the Ang II AT1
receptor. In line with our data, it has previously postu-
lated that AT1-AA may alter the structural conformation
of Ang II AT1 receptor so that the receptor’s ability
binding to circulating Ang II is enhanced [12].The CAM of chick embryo has widely been selected to
study the morphological aspects of tumor angiogenesis
and metastasis [20]. We chose the CAM of chick embryo
as a test model to demonstrate angiogenic substances in
our study because of its extensive vascularization and easy
accessibility to investigate mechanisms of action of
proangiogenic and antiangiogenic molecules [20]. We
found that addition of AT1-AA at the same dose that
causes OVCAR3 cell migration is effective in stimulating
angiogenesis in the CAM, which was parallel with data
showing elevation of VEGF in EOC patients. This in-
creased microvascular density elicited by AT1-AA was
comparable to the level as that in the Ang II group. Fur-
thermore, we showed that the use of AT1R-ECII or AT1
receptor blocker, losartan completely inhibits AT1-AA-in-
duced angiogenesis of the CAM. These findings suggest
that an enhancement of angiogenesis by AT1-AA involves
activation of Ang II AT1 receptor, thus selective Ang II
AT1 blockade therapy could efficiently inhibit the AT1-
AA-elicited angiogenesis under conditions exposed to
AT1-AA as it has previously been reported [19].
There are several limitations to this study that need to
be mentioned. First, although in vitro studies speculated
the mechanisms responsible for the migration of cancer
cells and angiogenesis through AT1 receptor, this study
did not measure AT1 receptor expression to show
whether such a change is associated with AT1-AA-medi-
ated effects. Second, although a raised titer of AT1-AA
was detected in EOC patients, the “cause-effect” rela-
tionship remains to be investigated. In this regard, it will
be interesting to determine whether the AT1-AA titer
falls in patients undergoing treatment. Third, the size of
the study population was relatively small and limited
only in the Asian patients. Therefore, future large-scale
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whether AT1-AA titer is also altered in EOC patients of
different ethnicities.
Conclusions
In summary, we found that serum AT1-AA is elevated in
higher proportion of EOC patients, which is associated
with advanced stages and pathological grades of EOC,
and appears to promote the ovarian call migration and
angiogenesis through Ang II AT1 receptor. This study
provides promising data showing that AT1-AA may play
a significant role in development and progression of
EOC, and might be considered as a potential therapeutic
target in treatment of EOC patients.
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